Anti-CD38 mAb Market to Accelerate Substantially During the Study Period Owing to a Strong Uptake of DARZALEX in Multiple Myeloma and Expected Entry of anti-CD38 mAbs in Autoimmune Diseases | DelveInsight

DelveInsight Business Research, LLP United States of America United Kingdom

[phone]

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/anti-cd38-mab-market-to-accelerate-substantially-during-the-study-period-20202034-owing-to-a-strong-uptake-of-darzalex-in-multiple-myeloma-and-expected-entry-of-anti-cd38-mabs-in-autoimmune-diseases--delveinsight-302284086.html